Tioga Medical, A Shifamed Portfolio Company, Closes $30M In Series B Financing

Cartessa Aesthetics’ Innovative Multi-Modality Treatment Leads Demand for Non-Invasive Body Procedures

PHYSIQ is a novel, dual-modality system that offers deep heat to target tissue and electrical muscle stimulation (EMS) to re-educate muscle – all from one device and in one session.

Radiaction Medical Ltd. Secures Additional Patents in US and Japan – En-Route to Commercialization of its Radiation Shielding Technology

"We are pleased by the ongoing validation of our radiation shielding technology's differentiation," said Mr. Jonathan Yifat, CEO of Radiaction Medical. "As we are nearing commercialization, these patents strengthen our strategic IP assets and further our mission to provide a safe environment for healthcare teams in the interventional suite," added Mr. Yifat.

The LimFlow System Found to be Cost-Effective, According to the Newest Study Published in the Journal of Critical Limb Ischemia

Percutaneous Deep Vein Arterialization (pDVA) with the LimFlow System offers a cost-effective and high-value alternative to traditional therapies or amputation in a new study, published June 2021.

Tioga Medical, Inc., a Shifamed portfolio company that aims to redefine structural heart valve replacement, announced today the initial closing of its committed $30M Series B financing. Led by The Capital Partnership (TCP), with participation from Cormorant Asset Management, AMED Ventures, and Shifamed angel investors, the financing will be used to advance product development, support pre-clinical testing, and initiate clinical experience for the company’s novel transcatheter valve replacement technology.

“Current valve replacement approaches are either surgically invasive, anatomically limited, or procedurally complex, hindering use despite the significant clinical need. Tioga’s proprietary technology aims to address these challenges with a less invasive, more adaptable transcatheter intervention,” commented Gautam Kainth, Managing Director at TCP. “We are pleased to lead this round and look forward to delivering this much-needed solution to this large and underserved segment of the structural heart market.”

Mitral valve disease is the company’s initial focus and is the largest structural heart valve problem, roughly four times more common than aortic stenosis.1,2 Directly tied to heart failure, mitral valve disease can increase cardiac workload and is associated with increased morbidity and mortality. Current surgical approaches are invasive and not widely utilized, leaving many patients undertreated. Similar to the recent adoption for transcatheter aortic valve replacement (TAVR), there is a significant clinical need for less invasive, transcatheter approaches for mitral valve replacement.

“We are extremely pleased to close this round of financing with strong, continued support from our investors, validating the clear unmet need in this space,” stated Mike Dineen, President and CEO of Tioga Medical. “We look forward to furthering our development efforts and demonstrating the performance of Tioga’s next-generation design to simplify and improve the safety and efficacy of transcatheter valve replacement procedures for both physicians and patients.”

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.